State of Michigan Retirement System grew its place in Exelixis, Inc. (NASDAQ:EXEL – Get Score) by 1.2% within the 4th quarter, in line with its most up-to-date disclosure with the SEC. The fund owned 82,116 shares of the biotechnology firm’s inventory after shopping for a further 1,000 shares throughout the interval. State of Michigan Retirement System’s holdings in Exelixis had been value $1,317,000 as of its most up-to-date SEC submitting.
A number of different massive traders have additionally purchased and offered shares of the corporate. Fulton Financial institution N.A. elevated its holdings in Exelixis by 6.3% throughout the third quarter. Fulton Financial institution N.A. now owns 10,765 shares of the biotechnology firm’s inventory valued at $169,000 after shopping for a further 640 shares over the last quarter. CWM LLC elevated its holdings in Exelixis by 12.8% throughout the third quarter. CWM LLC now owns 6,053 shares of the biotechnology firm’s inventory valued at $95,000 after shopping for a further 687 shares over the last quarter. Healthcare of Ontario Pension Plan Belief Fund elevated its holdings in Exelixis by 5.6% throughout the third quarter. Healthcare of Ontario Pension Plan Belief Fund now owns 13,253 shares of the biotechnology firm’s inventory valued at $208,000 after shopping for a further 703 shares over the last quarter. US Bancorp DE elevated its holdings in Exelixis by 1.1% throughout the third quarter. US Bancorp DE now owns 75,522 shares of the biotechnology firm’s inventory valued at $1,184,000 after shopping for a further 786 shares over the last quarter. Lastly, Louisiana State Workers Retirement System elevated its holdings in Exelixis by 0.9% throughout the fourth quarter. Louisiana State Workers Retirement System now owns 86,400 shares of the biotechnology firm’s inventory valued at $1,386,000 after shopping for a further 800 shares over the last quarter. 84.74% of the inventory is owned by hedge funds and different institutional traders.
Insider Exercise at Exelixis
In different information, Director Jack L. Wyszomierski offered 15,300 shares of the inventory in a transaction dated Friday, March tenth. The shares had been offered at a mean worth of $16.61, for a complete transaction of $254,133.00. Following the sale, the director now owns 317,467 shares of the corporate’s inventory, valued at $5,273,126.87. The sale was disclosed in a submitting with the Securities & Change Fee, which may be accessed by way of the SEC web site. In different Exelixis information, Director Jack L. Wyszomierski offered 15,300 shares of the inventory in a transaction that occurred on Friday, March tenth. The shares had been offered at a mean worth of $16.61, for a complete worth of $254,133.00. Following the transaction, the director now immediately owns 317,467 shares within the firm, valued at $5,273,126.87. The sale was disclosed in a authorized submitting with the Securities & Change Fee, which is accessible by way of the SEC web site. Additionally, EVP Patrick J. Haley offered 25,000 shares of the agency’s inventory in a transaction that occurred on Monday, February sixth. The inventory was offered at a mean worth of $17.37, for a complete transaction of $434,250.00. Following the transaction, the chief vice chairman now owns 254,414 shares within the firm, valued at $4,419,171.18. The disclosure for this sale may be discovered right here. During the last quarter, insiders offered 237,100 shares of firm inventory valued at $4,212,089. 2.90% of the inventory is owned by firm insiders.
Exelixis Worth Efficiency
EXEL opened at $19.64 on Friday. The agency has a fifty day transferring common worth of $18.06 and a 200 day transferring common worth of $17.01. Exelixis, Inc. has a 1 yr low of $14.87 and a 1 yr excessive of $23.29. The inventory has a market cap of $6.37 billion, a P/E ratio of 34.46, a P/E/G ratio of 0.83 and a beta of 0.68.
Exelixis (NASDAQ:EXEL – Get Score) final posted its earnings outcomes on Tuesday, February seventh. The biotechnology firm reported ($0.09) earnings per share (EPS) for the quarter, lacking the consensus estimate of ($0.05) by ($0.04). The agency had income of $423.92 million throughout the quarter, in comparison with analyst estimates of $418.71 million. Exelixis had a internet margin of 11.31% and a return on fairness of seven.54%. The enterprise’s income for the quarter was down 6.0% on a year-over-year foundation. Throughout the identical quarter within the prior yr, the agency earned $0.29 earnings per share. Equities analysts anticipate that Exelixis, Inc. will put up 0.66 EPS for the present yr.
Wall Road Analysts Forecast Development
Quite a few brokerages have commented on EXEL. Piper Sandler reaffirmed an “obese” score and set a $32.00 goal worth on shares of Exelixis in a report on Wednesday, February eighth. Credit score Suisse Group started protection on shares of Exelixis in a report on Thursday, January twenty sixth. They set an “outperform” score and a $29.00 goal worth for the corporate. EF Hutton Acquisition Co. I reiterated a “purchase” score and issued a $24.00 worth goal on shares of Exelixis in a analysis report on Friday, March third. JMP Securities dropped their worth goal on shares of Exelixis from $25.00 to $24.00 and set a “market outperform” score for the corporate in a analysis report on Thursday, January nineteenth. Lastly, Cowen dropped their worth goal on shares of Exelixis from $21.00 to $20.00 in a analysis report on Monday, January ninth. One analyst has rated the inventory with a maintain score and 9 have given a purchase score to the corporate’s inventory. In line with MarketBeat.com, Exelixis has a consensus score of “Reasonable Purchase” and a consensus worth goal of $25.92.
Exelixis Profile
(Get Score)
Exelixis, Inc operates as an oncology firm, which focuses on discovering, growing, and commercialization of recent medicines for difficult-to-treat cancers. Its merchandise embrace cabometyx, cometriq, and cotellic. The corporate was based by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
See Additionally
Obtain Information & Scores for Exelixis Every day – Enter your e-mail deal with beneath to obtain a concise each day abstract of the newest information and analysts’ scores for Exelixis and associated firms with MarketBeat.com’s FREE each day e-mail publication.
